ClinicalTrials.gg
RecruitingNCT05463133Updated Oct 13, 2026

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

A Phase 1/2 interventional study of Sirolimus and Cyclophosphamide in Chronic Granulomatous Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 4 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Updated Oct 2, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
4 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) — 7 open to participants now, 10 under way, none of them phase 3. Granulomatous Disease, Chronic · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
5th of 24
50 · median 10
Started
2022
with 2 others
Phase 1/2
8 of 31
4 open now
Registered
27th of 31
by date

Among the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 5th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2022, is one of 8 in phase 1/2, and was the 27th registered.

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

Browse Granulomatous Disease, Chronic studies →

Open to participants now

7 of the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 12 Granulomatous Disease, Chronic studies recruiting now, 3 (25%) set no upper age limit and 9 (75%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 4 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Chronic granulomatous disease (CGD) affects the immune system. People with CGD are more likely to get infections. Drugs can help control infections, but these treatments can cause side effects including kidney failure and deafness. Stem cell transplants can cure CGD, but these don t always work.

Objective:

To find out if a different drug treatment can improve the success rates of stem cell transplants in people with CGD.

Eligibility:

People aged 4-65 years with CGD.

Design:

Participants will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of their heart function and breathing. They will have imaging scans. They will have a bone marrow biopsy; a needle will be inserted into their hip to draw a sample of tissue from the bone.

A tube called a catheter will be placed into a vein in the participant s chest. This catheter will remain in place for the transplant and recovery period. Blood for tests can be drawn from the catheter, and medications and the stem cells can be administered through it.

Participants will be in the hospital for either 10 or 21 days to receive 3 or 4 drugs before the transplant. They will get 2 doses of total body radiation on the same day.

Participants will receive donor stem cells through the catheter. They will remain in the hospital for 6 weeks afterward.

Participants will visit the clinic 2 to 3 times per week for 3 months after discharge.

Follow-up visits will continue for 5 years.

Read the detailed description

Chronic Granulomatous Disease (CGD) is an inherited disorder resulting from a failure to produce nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, necessary for protection against a number of infectious organisms. Patients are subject to recurrent infections and inflammatory complications. The current management of these patients is limited to close surveillance for infections, administration of prophylactic antimicrobials, and rapid and aggressive treatment of suspected and documented infections with broad-spectrum antibiotics. Although often effective, these treatments can require long hospitalizations, impacting the overall quality of life significantly and leading to significant morbidity, such as renal failure and deafness. CGD patients have autoinflammation that may manifest as inflammatory bowel disease, hypoxic lung inflammation, and/or liver nodular regenerative hyperplasia with venopathy as examples.

Currently the only available cure for these disorders is bone marrow transplantation, which preferentially uses a human leukocyte antigen (HLA)-matched related sibling as the donor (allogeneic stem cell transplantation). However, as only 30% of participants in the general

population have an HLA-matched related sibling, allogeneic related transplantation is often not an option, resulting in the need for matched unrelated donor (MUD) transplantation. The National Marrow Donor Program (NMDP) serves as both a national registry of volunteers who are willing to donate progenitor cells to eligible recipients as well as a repository of cord blood products. Despite continued improvement in the use of transplantation schemas - including the development of nonmyeloablative regimens - there remain significant morbidity and mortality associated with transplantation, in particular graft versus host disease (GvHD) and graft rejection.

CGD with severe autoinflammation manifested as C-reactive protein (CRP) >= 100 milligrams per milliliter (mg/mL) has been a significant risk factor for mortality due to severe engraftment syndrome, and thus patients with elevated CRPs have not been eligible for prior transplant protocols.

In addition, despite improving engraftment rates, there continues to be mixed chimerism and late graft loss in CGD participants despite a variety of conditioning regimens being used at various centers.

In our most recent protocol, we have continued to have a low incidence of graft versus host disease and improved engraftment, but still could see improvement in graft stability. Thus, in order to improve outcomes with participants with elevated CRPs as well as improve overall engraftment, we are building on our prior regimens by targeting the inflammatory cytokines that appear to be involved in graft failure and engraftment syndrome.

Participants with a CRP of less than 100 mg/mL will be pretreated with a dose of tocilizumab, an anti-IL6 monoclonal antibody. Participants with a CRP of greater than 100 mg/mL will be pretreated with 2 doses of tocilizumab as well as an inhibitor of interferon-gamma in order to decrease the inflammation that has been seen in these participants with engraftment. Otherwise, the conditioning regimen will be similar to maintain the low rates of GvHD that we have seen to date.

03

Conditions studied

  • Chronic Granulomatous Disease

Keywords

  • HLA Matched Related Donor
  • Matched Unrelated Donor
  • The National Marrow Donor Program
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
4 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all the following criteria:

  • Must have the ability to comprehend and a willingness to sign the . For pediatric patients, must have a parent/guardian who can sign consent if the donor is a minor; assent will be obtained from minors as appropriate.
  • Must have confirmed diagnosis of CGD.
  • Must have sufficient complications from underlying disease to warrant undergoing transplantation (either a history of or ongoing inflammation/CGD-related autoimmunity OR a CGD-related infection while on prophylaxis) OR have a Quartile 1 or 2 residual oxidase production level.
  • Ages 4 years-65 years.
  • HLA-matched family donor graft or an HLA-matched unrelated PBSC graft (10/10 or 9/10 mismatch) available.
  • Must be (HIV) negative.
  • When discharged from the hospital the participant must be able to stay within 1 hour's travel of the NIH for the first 3 months after transplantation.
  • Must have a family member or other designated care provider to assist with care during the post-transplant period when the patient is in the outpatient setting.
  • Must provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance with NIH 200 "NIH Durable Power of Attorney for Health Care Decision Making."
  • Females of must agree to consistently use one form of from 1 month prior to study entry and for at least 1 year post transplant. Male participants must agree to consistently use contraception for 1 year post transplant. Acceptable forms of contraception are:

    • Contraceptive pills or patch, Norplant [Registered], Depo-Provera [Registered], or other FDA-approved contraceptive method.
    • Male partner has previously undergone a vasectomy.
    • Male participants will be advised to consistently use contraception throughout study participation and for 3 months post-transplant.
  • Stated willingness to comply with all study procedures and is available for protocol visits for the duration of the study when possible.
  • Patients who have a CRP of greater than 100 but otherwise meet inclusion criteria will be enrolled on the high-risk arm.

    • CRP will be assessed no more than 7 weeks and no less than 6 weeks prior to anticipated transplant to determine on which arm the patient will be treated.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • of less than 30% by echocardiography.
  • (FEV1%) of less than 35% and/or an adjusted diffusing capacity of lung of carbon monoxide (adj DLCO) of less than 30%.
  • Transaminases >5x based on the individual s clinical situation and at the discretion of the investigator.
  • Psychiatric disorder or mental deficiency severe enough as to make compliance with the treatment unlikely, and/or to make regulatorily and legally effective impossible.
  • Major anticipated illness or organ failure incompatible with survival from allogeneic peripheral blood stem cell (AlloPBSC) transplant.
  • Pregnant or lactating.
  • Uncontrolled seizure disorder per principal investigator (PI) discretion.
  • Individuals older than 65 years are excluded. It is known from standard transplantation that these individuals have a higher risk of morbidity and mortality related to transplantation. Given the nature of this protocol, the risk-benefit ratio is not warranted to include these individuals at this time.
  • Active TB infection.
  • Any condition or circumstance that the PI feels would create difficulty in maintaining compliance with the requirements of this protocol.
  • Individuals who are not willing to submit their information as part of the alemtuzumab (Campath [Registered]) Distribution Program application or participants whom the Distribution Program committee has determined are not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (Campath-1H) (intravenous [IV] formulation) is no longer distributed commercially. To receive product, the physician must contact the program for the patient. If the patient is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then we cannot proceed with conditioning; therefore no transplant will occur on this protocol. http://www.campath.com/

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Arm 1 / Group 1 Standard Risk

    Group 1 (Standard group) will receive tociluzumab at Day -10, Alemtuzumab on Day -9,-8,-7,-6,-5; Busulfan on Day -4, and -3, TBI, matched donor PBSC infusion, and Post transplant Cyclophosphamide.

    Drug: Sirolimus · Drug: Cyclophosphamide · Drug: Alemtuzumab · Drug: Busulfan · Biological: Pheripheral blood stem cells · Drug: Tociluzumab · Drug: Total Body Irradiation

  • Experimental
    Arm 2 / Group 2 High Risk.

    Group 2 (High risk group will receive tociluzumab at day -24, a repeat dose at day -19, Alemtuzumab at day -9,-8,-7,-6,-5; Busulfan at day -4 and -3, Emapalumab at Day -1, matched donor PBSC infusion, and post transplant cyclophosphamide at Day +3 and +4

    Drug: Sirolimus · Drug: Cyclophosphamide · Drug: Alemtuzumab · Drug: Busulfan · Biological: Pheripheral blood stem cells · Drug: Emapalumab-Izsg · Drug: Tociluzumab

Interventions

  • Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.

  • Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.

  • Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.

  • Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.

  • BiologicalPheripheral blood stem cells

    Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.

  • DrugEmapalumab-Izsg

    Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.

  • DrugTocilizumabStudies of TocilizumabTocilizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.

  • DrugTotal Body Irradiation

    Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Alive at 1 years post-transplant.

    Time frame: 1 years post-transplant.

Secondary outcomes

  1. To assess the infection rates in the setting of Alemtuzumab (Campath-1H) and post-transplant cyclophosphamide with the addition of an Il-6 antagonist and TNF inhibitor.

    Any documented viral, bacterial, fungal, or parasitic infection.

    Time frame: Day 100, 6 months, 1 and/or 2 years post BMT

  2. To assess kinetics of engraftment

    Measurement of chimerism, lymphocyte phenotype (TBNK/SCID/TVB), and cytokine analysis laboratory values and research cytokine, alemtuzumab, and CXCL9 levels

    Time frame: Day +14, +30, +60, +100, 6 month and 1 year post transplant

  3. Improve eligibility for allogeneic transplantation.

    Subject eligible to enroll in the protocol.

    Time frame: Eligibility determination for protocol enrollment

  4. Engraftment without GvHD

    As defined by a \>10-20% myeloid engraftment of donor neutrophils. Will be assess as event-free survival (EFS)

    Time frame: Day 100, 6 months, and/or 1 year post BMT

  5. Decreased engraftment syndrome.

    Engraftment syndrome symptoms such as fever, erythrodermal rash, noncardiogenic pulmonary edema, hepatic dysfunction, renal insufficiency, weight gain and transient encephaopathy that is responsive to steroids and/or tocilizumab, and does not require ICU admission or lead to death.

    Time frame: 30 days post transplant.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Parta M, Kelly C, Kwatemaa N, Theobald N, Hilligoss D, Qin J, Kuhns DB, Zerbe C, Holland SM, Malech H, Kang EM. Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial. J Clin Immunol. 2017 Aug;37(6):548-558. doi: 10.1007/s10875-017-0422-6. Epub 2017 Jul 28. PubMed 28752258 ↗
  • Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 Mar 10;39(8):920-930. doi: 10.1200/JCO.20.02477. Epub 2021 Jan 8. PubMed 33417474 ↗
  • Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, Schulz A, Hoenig M, Hauck F, Al Seraihy A, Gozdzik J, Ljungman P, Lindemans CA, Fernandes JF, Kalwak K, Strahm B, Schanz U, Sedlacek P, Sykora KW, Aksoylar S, Locatelli F, Stepensky P, Wynn R, Lum SH, Zecca M, Porta F, Taskinen M, Gibson B, Matthes S, Karakukcu M, Hauri-Hohl M, Veys P, Gennery AR, Lucchini G, Felber M, Albert MH, Balashov D, Lankester A, Gungor T, Slatter MA. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020 Sep 3;136(10):1201-1211. doi: 10.1182/blood.2020005590. PubMed 32614953 ↗

Individual participant data

Plan to share: Yes — The following date will be shared:@@@@@@All the individual participant data collected during the trial, after de-identification.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data availability and the duration of the data availability are as follows: Transplant data shared with the following groups will be shared at the onset of the signing of the protocol and will be maintained in shared data bases with no end date. (BTRIS), Neutrophil Monitoring Laboratory (NML), The NIH and other government agencies, like the Food and Drug Administration (FDA), which are involved in keeping research safe for people, NIH Intramural Institutional Review Board, The Center for Blood and Marrow Transplant Research, Study sponsor (NIAID), NHLBI s Data Safety and Monitoring Board, Blood and Inherited Disorder-Transplant and Cellular Therapy Program, Study monitors (NIAID/Office of Clinical Research Policy and Regulatory Operations NIAID/OCRPRO). Transplant data submitted for publication will be immediately available following publication with no end date.

Access criteria: Individual deidentified participant data will be shared with: A public repository, (CIBMTR), as required by the Stem Cell Act 2005 through the Forms Net database system. An NIH-funded or approved public repository. Publications, Public presentations, Individual identified participant data will be shared, approved outside collaborators under appropriate agreements, such as the NMLab in Md. Identified data in (BTRIS). The following data will be shared: All the individual participant data collected during the trial, after deidentification. The following related documents will be available: Study Protocol, Statistical analysis plan, Analytic code. Data and the duration of the data availability are as follows: Transplant data shared with CIBMTR, BTRIS, and the NML will be shared at the onset of signing the protocol and will be maintained in shared databases with no end date. Transplant data submitted for publication will be immediately available following publication with no end date.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2032, 125 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2022
First posted
Jul 18, 2022
StartActual
Jul 8, 2022
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedWhen discharged from the hospital the participant must be able to stay within 1 hour 's travel of the NIH for the first 3 months after transplantation.
  • EditedMust provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance with NIH 200 '"NIH Durable Power of Attorney for Health Care Decision Making.'"
Oct 2, 2026
Show all 4 updates
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 2, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedWhen discharged from the hospital the participant must be able to stay within 1 hour 's travel of the NIH for the first 3 months after transplantation.
    • EditedMust provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance with NIH 200 '"NIH Durable Power of Attorney for Health Care Decision Making.'"

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05463133
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Jul 8, 2022
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Sandra M Maxwell, R.N.
Contact
maxwells@mail.nih.gov
(240) 627-3078
Elizabeth M Kang, M.D.
Contact
ekang@niaid.nih.gov
(301) 402-7567
Elizabeth M Kang, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion